🚀 VC round data is live in beta, check it out!
Diasorin Valuation Multiples
Discover revenue and EBITDA valuation multiples for Diasorin and similar public comparables like Telix Pharmaceuticals, Genscript Biotech, MGI Tech, Sotera Health and more.
Diasorin Overview
About Diasorin
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics used for detecting pathogens and contamination of samples from the human body, as well as used in industrial settings such as food and water contamination testing. The company operates three segments: immunodiagnostics (66% of sales), molecular diagnostics (17%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment’s importance has decreased over the years, and in 2024, it accounted for only 2% of total sales.
Founded
1968
HQ
Employees
3.3K
Website
Financials (LTM)
EV
$4B
Diasorin Financials
Diasorin reported last 12-month revenue of $1B and EBITDA of $458M.
In the same LTM period, Diasorin generated $907M in gross profit, $458M in EBITDA, and $188M in net income.
Revenue (LTM)
Diasorin P&L
In the most recent fiscal year, Diasorin reported revenue of $1B and EBITDA of $455M.
Diasorin expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $907M | XXX | $911M | XXX | XXX | XXX |
| Gross Margin | 65% | XXX | 65% | XXX | XXX | XXX |
| EBITDA | $458M | XXX | $455M | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 32% | XXX | XXX | XXX |
| EBIT Margin | 24% | XXX | 24% | XXX | XXX | XXX |
| Net Profit | $188M | XXX | $183M | XXX | XXX | XXX |
| Net Margin | 13% | XXX | 13% | XXX | XXX | XXX |
| Net Debt | — | — | $657M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Diasorin Stock Performance
Diasorin has current market cap of $4B, and enterprise value of $4B.
Market Cap Evolution
Diasorin's stock price is $73.17.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4B | $4B | 0.0% | XXX | XXX | XXX | $3.64 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDiasorin Valuation Multiples
Diasorin trades at 3.1x EV/Revenue multiple, and 9.5x EV/EBITDA.
EV / Revenue (LTM)
Diasorin Financial Valuation Multiples
As of April 19, 2026, Diasorin has market cap of $4B and EV of $4B.
Equity research analysts estimate Diasorin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Diasorin has a P/E ratio of 19.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV/Revenue | 3.1x | XXX | 3.1x | XXX | XXX | XXX |
| EV/EBITDA | 9.5x | XXX | 9.6x | XXX | XXX | XXX |
| EV/EBIT | 13.1x | XXX | 13.1x | XXX | XXX | XXX |
| EV/Gross Profit | 4.8x | XXX | 4.8x | XXX | XXX | XXX |
| P/E | 19.6x | XXX | 20.1x | XXX | XXX | XXX |
| EV/FCF | 22.1x | XXX | 18.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Diasorin Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Diasorin Margins & Growth Rates
Diasorin's revenue in the last 12 month grew by 6%.
Diasorin's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Diasorin's rule of 40 is 35% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Diasorin's rule of X is 41% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Diasorin Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 32% | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | 2% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 35% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 41% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 24% | XXX | 24% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 11% | XXX | 11% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 8% | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 42% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Diasorin Public Comps
See public comps and valuation multiples for other Laboratory Services and Medical Imaging & Diagnostics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Diasorin | XXX | XXX | XXX | XXX | XXX | XXX |
| Telix Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Genscript Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| MGI Tech | XXX | XXX | XXX | XXX | XXX | XXX |
| Sotera Health | XXX | XXX | XXX | XXX | XXX | XXX |
| HeartFlow | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Diasorin M&A Activity
Diasorin acquired XXX companies to date.
Last acquisition by Diasorin was on XXXXXXXX, XXXXX. Diasorin acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Diasorin
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDiasorin Investment Activity
Diasorin invested in XXX companies to date.
Diasorin made its latest investment on XXXXXXXX, XXXXX. Diasorin invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Diasorin
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Diasorin
| When was Diasorin founded? | Diasorin was founded in 1968. |
| Where is Diasorin headquartered? | Diasorin is headquartered in Italy. |
| How many employees does Diasorin have? | As of today, Diasorin has over 3K employees. |
| Who is the CEO of Diasorin? | Diasorin's CEO is Carlo Rosa. |
| Is Diasorin publicly listed? | Yes, Diasorin is a public company listed on Borsa Italiana. |
| What is the stock symbol of Diasorin? | Diasorin trades under DIA ticker. |
| When did Diasorin go public? | Diasorin went public in 2007. |
| Who are competitors of Diasorin? | Diasorin main competitors are Telix Pharmaceuticals, Genscript Biotech, MGI Tech, Sotera Health. |
| What is the current market cap of Diasorin? | Diasorin's current market cap is $4B. |
| What is the current revenue of Diasorin? | Diasorin's last 12 months revenue is $1B. |
| What is the current revenue growth of Diasorin? | Diasorin revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Diasorin? | Current revenue multiple of Diasorin is 3.1x. |
| Is Diasorin profitable? | Yes, Diasorin is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Diasorin? | Diasorin's last 12 months EBITDA is $458M. |
| What is Diasorin's EBITDA margin? | Diasorin's last 12 months EBITDA margin is 33%. |
| What is the current EV/EBITDA multiple of Diasorin? | Current EBITDA multiple of Diasorin is 9.5x. |
| What is the current FCF of Diasorin? | Diasorin's last 12 months FCF is $198M. |
| What is Diasorin's FCF margin? | Diasorin's last 12 months FCF margin is 14%. |
| What is the current EV/FCF multiple of Diasorin? | Current FCF multiple of Diasorin is 22.1x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.